List Of Adverse Effects Of Nilotinib

This is a list of adverse effects of the anti-cancer drug nilotinib, sorted by frequency of occurrence.^[1]^[2]^[3]^[4]^[5]^[6]

Very common[edit | edit source]

Very common (>10% incidence) adverse effects include:

Headache
Nausea
Hypophosphataemia
Hyperbilirubinaemia
Alanine aminotransferase (ALT) increased
Aspartate aminotransferase increased
Lipase increased
Rash
Itchiness
Hair loss
Dry skin
Muscle aches
Fatigue

Common[edit | edit source]

Common (1–10% incidence) adverse effects include:

Constipation
Diarrhoea
Vomiting
Upper abdominal pain
Indigestion
Joint pain
Muscle spasms
Pain in extremities
Asthenia
Peripheral oedema
Folliculitis
Upper respiratory tract infection (including pharyngitis, nasopharyngitis, rhinitis)
Skin papilloma
Eosinophilia
Lymphopenia
Insomnia
Anxiety
Depression
Diabetes mellitus
Hypercholesterolaemia
Hyperlipidaemia
Hypertriglyceridaemia
Hyperglycaemia
Loss of appetite
Dizziness
Hypoaesthesia
Peripheral neuropathy
Eye pruritus
Conjunctivitis
Dry eye (including xerophthalmia)
Vertigo
Flushing
Hypertension
Angina pectoris
Arrhythmia (including atrioventricular block, tachycardia, atrial fibrillation, ventricular extrasystoles, bradycardia)
QT interval prolonged
Palpitations
Cough
Dyspnoea
Abdominal distension
Abdominal discomfort
Taste changes
Flatulence
Abnormal liver function
Bone pain
Back pain
Erythema
Hyperhidrosis
Contusion
Acne
Dermatitis (including allergic, exfoliative and acneiform)
Night sweats
Fever without an infectious cause
Chest pain (including non-cardiac chest pain)
Chest discomfort
Decreased haemoglobin
Increased blood amylase
Increased blood alkaline phosphatase
Gamma-glutamyltransferase increased
Weight increased
Increased blood insulin
Increased lipoprotein (including very low density and high density)

Uncommon[edit | edit source]

Uncommon (0.1–1% incidence) adverse effects include:

Arteriosclerosis
Bone marrow suppression
Both increases and decreases of potassium levels
Body temperature change sensation (both hot and cold)
Chills
Cognitive deficits^[7]
Conjunctival bleeding and redness
Cyanosis
Dental sensitivity to pain
Bleeding into the lungs^[8]
Increased blood cholesterol and lipid levels
Dystonia^[7]
Erectile dysfunction
Eyelid swelling
Flank pain
Gastritis
Gout
Decreased calcium levels
Jaundice
Malaise
Migraine
Muscle pain and weakness
Pancreatitis
Paraesthesia
Peripheral arterial occlusive disease
Photopsia
Pleural effusion
Skin eruptions
Skin pain
Decreased globulins

References[edit | edit source]

↑ "Complete Nilotinib information from Drugs.com". Drugs.com. Archived from the original on 1 February 2014. Retrieved 25 January 2014.
↑ "Tasigna : EPAR - Product Information" (PDF). European Medicines Agency. Novartis Europharm Ltd. 18 October 2013. Archived (PDF) from the original on 4 February 2014. Retrieved 25 January 2014.
↑ "Tasigna 150mg Hard Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd. 9 September 2013. Archived from the original on 1 February 2014. Retrieved 25 January 2014.
↑ "TASIGNA® nilotinib" (PDF). TGA eBusiness Services. 21 October 2013. Archived from the original on 6 April 2017. Retrieved 25 January 2014.
↑ "Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 17 July 2021. Retrieved 25 January 2014.
↑ Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
↑ ^7.0 ^7.1 Chan, J; Shah, P; Moguel-Cobos, G (2019). "Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia". Case Reports in Neurological Medicine. 2019: 3679319. doi:10.1155/2019/3679319. PMC 6875312. PMID 31781436.
↑ Donatelli, C., D. Chongnarungsin, and R. Ashton. (Oct 2014). "Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage". Leuk Lymphoma. 55 (10): 2408–9. doi:10.3109/10428194.2014.887714. PMID 24467220. S2CID 43118790.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Drugs-1] "Complete Nilotinib information from Drugs.com". Drugs.com. Archived from the original on 1 February 2014. Retrieved 25 January 2014.

[EMA-2] "Tasigna : EPAR - Product Information" (PDF). European Medicines Agency. Novartis Europharm Ltd. 18 October 2013. Archived (PDF) from the original on 4 February 2014. Retrieved 25 January 2014.

[EMC-3] "Tasigna 150mg Hard Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd. 9 September 2013. Archived from the original on 1 February 2014. Retrieved 25 January 2014.

[TGA-4] "TASIGNA® nilotinib" (PDF). TGA eBusiness Services. 21 October 2013. Archived from the original on 6 April 2017. Retrieved 25 January 2014.

[MSR-5] "Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 17 July 2021. Retrieved 25 January 2014.

[AMH-6] Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.

[Parkinsonism-7] 7.0 ^7.1 Chan, J; Shah, P; Moguel-Cobos, G (2019). "Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia". Case Reports in Neurological Medicine. 2019: 3679319. doi:10.1155/2019/3679319. PMC 6875312. PMID 31781436.

[8] Donatelli, C., D. Chongnarungsin, and R. Ashton. (Oct 2014). "Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage". Leuk Lymphoma. 55 (10): 2408–9. doi:10.3109/10428194.2014.887714. PMID 24467220. S2CID 43118790.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]